In summary, our findings suggest that anti-ANGPTL3/IL22 fusion protein protects the kidney by reducing proteinuria and renal fibrosis as well as stabilizing the endocrine environment in the treatment of DN. This evidence concerns the gene IL22 and liver dysplastic nodule.